Alvotech Merges with Oaktree Acquisition Corp. II and Lists on Nasdaq

Avant Technologies Proposes Acquisition of Ainnova Tech to Consolidate Vision AI JV

May 13, 2025

Healthcare Services

Avant Technologies has entered formal negotiations to acquire its joint-venture partner Ainnova Tech (operating through Ai-nova Acquisition Corp.), aiming to merge the businesses ahead of an FDA pre-submission meeting. The deal is intended to streamline regulatory coordination, speed clinical development and support U.S. market entry for the Vision AI clinical screening platform currently piloted across Latin America.

Vertex Pharmaceuticals Acquires Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $65 per share (approximately $4.9 billion) in cash. The acquisition adds Alpine’s lead candidate povetacicept (ALPN‑303) and protein-engineering/immunotherapy capabilities to Vertex’s pipeline and is expected to close in Q2 2024, subject to customary conditions.

Roivant Sciences to Combine with Montes Archimedes Acquisition Corp. (MAAC) and Go Public as ROIV

May 3, 2021

Biotechnology

Roivant Sciences entered into a definitive business combination agreement with Montes Archimedes Acquisition Corp. (MAAC), a SPAC sponsored by Patient Square Capital, to take Roivant public on Nasdaq under the ticker ROIV. The transaction is expected to provide up to $611 million of gross proceeds (including a $200 million PIPE) to fund discovery and development programs and extend Roivant's operating runway through mid-2024.

Sequoia Financial Group Acquires AltruVista

April 2, 2024

Financial Services

Sequoia Financial Group, an Akron-based SEC-registered wealth manager with more than $18 billion AUM, has acquired Houston-based AltruVista, an SEC-registered investment adviser with roughly $310 million in AUM. The deal, which closed March 31, 2024, adds a Houston office to Sequoia's footprint and brings AltruVista founder Ali Nasser in as a Sequoia shareholder to continue supporting clients and share his Wealth Integration System for entrepreneurs.

EQT (via Otello BidCo AB) Acquires OX2 AB

October 8, 2024

Energy

EQT Infrastructure VI, through acquisition vehicle Otello BidCo AB, completed a recommended public offer to acquire 100% of OX2 AB at SEK 60 per share and now controls 98.81% of the company; OX2 has applied for delisting from Nasdaq Stockholm. EQT says it will support OX2's evolution from a pure developer to an integrated renewables developer and asset owner and provide additional investment to grow the company's pipeline across onshore/offshore wind, solar and storage.

PureTech Acquires Remaining Interest in Alivio Therapeutics

June 16, 2021

Biotechnology

PureTech Health plc acquired the remaining 22% of shares in its Founded Entity, Alivio Therapeutics, integrating Alivio's anti-inflammatory therapeutic programs — including LYT-500 and LYT-503/IMB-150 — into PureTech's Wholly Owned Pipeline. The transaction consolidates PureTech's ownership of Alivio and is expected to fund and advance the programs through PureTech's immunology and related technology capabilities.